Projected GLP-1 Trends for 2026

Key Takeaways:

• In 2026, the use of GLP-1 agonists is expected to expand, including FDA approval for the treatment of peripheral arterial disease and specific forms of heart failure.
• New injectable GLP-1 drugs are progressing through clinical trials, with CagriSema (a combination of Cagrilintide and Semaglutide) the furthest along, with an FDA response expected in 2026. 
• Oral GLP-1 drugs are becoming more widely available: Wegovy tablets were launched in January 2026, while the non-peptide GLP-1, Orforglipron, is expected to be approved in the latter part of 2026.
• Direct-to-consumer access to GLP-1 drugs continues to grow, changing the way people start and finance their treatments.

Glucagon-like peptide-1 (GLP-1) receptor agonists were originally developed for the treatment of Type 2 Diabetes but have completely changed the weight-loss drug market. Their popularity has been growing rapidly in recent years due to their high efficiency.

In 2026, significant changes await us in the world of GLP-1 therapies – from new indications to easier access to drugs. Here’s what the experts think.

What are GLP-1 Receptor Agonists?

GLP-1 receptor agonists mimic the natural gut hormone GLP-1, which plays a key role in regulating blood sugar levels, appetite, and digestion. GIP/GLP-1 receptor agonists act similarly but combine the effects of GLP-1 with the additional action of the hormone glucose-dependent insulinotropic polypeptide (GIP), thereby providing additional benefits.

Most GLP-1 drugs are given by injection, but there are also two oral options: Rybelsus and the tablet Wegovy, both with Semaglutide. Currently, the FDA has approved 11 GLP-1 drugs.

1.  Expanded Uses and Higher Doses

In 2026, GLP-1 drugs will no longer be just a Type 2 Diabetes therapy or a simple weight loss drug. These drugs are increasingly recognized as versatile therapies that can provide multiple benefits, including improving kidney, heart, liver, and other organ functions.

Possible new indications for GLP-1 drugs in 2026 include:

• Heart failure with preserved ejection fraction (HFpEF): Semaglutide shows great potential for the treatment of HFpEF in people diagnosed with obesity. Since obesity can contribute to the development of HFpEF and worsen symptoms, GLP-1 drugs appear to be a natural therapeutic choice. Wegovy is currently undergoing FDA review for this application.
• Peripheral artery disease (PAD): PAD is common in people with Type 2 Diabetes and can cause leg pain and difficulty walking. Ozempic is under FDA review for PAD, and studies so far show it can improve walking distance and quality of life.

Other indications currently under investigation include polycystic ovary syndrome (PCOS) and substance use disorders. These areas represent new therapeutic fields for GLP-1 agonists but are still in early clinical evaluation.

In addition to expanding indications, higher doses are also being considered. The highest currently approved dose of Wegovy is 2.4 mg, while a 7.2 mg dose is under consideration by the FDA. Results of clinical studies showed that subjects receiving a 7.2 mg dose achieved an average weight loss of approximately 19% from baseline.

Among subjects who received this type of therapy throughout the study period, a weight loss of almost 21% was recorded.

2.  New injectable GLP-1s

Multiple new injectable GLP-1 therapies are currently in various stages of clinical development. The goal of such tests is to achieve greater efficiency in reducing body weight than the already existing therapeutic options. Among the drugs closest to regulatory approval, CagriSema stands out, with potential approval in 2026.

CagriSema is a combination of Semaglutide and Cagrilintide. Cargrilintide is a long-acting analog of amylin – a hormone that can contribute to appetite regulation and increase the feeling of satiety after a meal. By combining a GLP-1 agonist with an amylin analog, a synergistic effect is achieved, with results so far indicating greater body weight reduction than with monotherapy.

According to clinical studies, subjects who received CagriSema therapy achieved an average loss of approximately 20% of initial body weight after 68 weeks (about 16 months). Among participants who received therapy throughout the trial, the average weight loss was approximately 23%.

A direct comparative trial of CagriSema therapy and Tirzepatide, which is currently considered one of the most effective drugs in the field of pharmacological body weight reduction, is underway. The results of this study are expected in 2026.

Additionally, CagriSema is being evaluated as a therapeutic option for weight control in patients with Type 2 Diabetes, and potential cardiovascular benefits in patients with existing heart pathology are also being actively investigated.

Other injectable GLP-1 candidates advancing through the clinical stages include:

• Retatrutide
• Survodutide
• VK2735

3.  Oral Options

Administration of injection therapy can be an obstacle for a large number of patients, so the development of oral GLP-1 agonists represents a significant step towards wider therapeutic acceptance. Following the introduction of the Weogovy tablet in January 2026, interest in non-invasive therapeutic options has grown significantly.

Oral Semaglutide – available under the trade names such as Wegovy, Ozempic, and Rybelsus – remains the only GLP-1 receptor agonist in tablet form. However, another official approval for the use of Orforglipron is expected during the second quarter of 2026.

Unlike existing peptide GLP-1 agonists, Orforglipron is a small-molecule agonist that does not rely on a peptide backbone. This molecule is synthesized by chemically linking simpler molecular units, potentially enabling a more efficient, stable, and favorable production process than peptide therapies.

The results of previous research and clinical trials indicate that subjects who received the highest tested dose of Orforglipron achieved an average reduction in body weight of approximately 11% over 72 weeks (about 17 months). Available data suggest that this drug’s administration was associated with maintenance of previously achieved weight loss in patients initially treated with injectable therapies such as Wegovy and Zepbound.

4.  Direct – to – Consumer Access

Direct – to – Consumer (DTC) model over time, it has become one of the key trends in the evolution of approaches to GLP-1 therapies. In 2026, many patients started therapy outside the traditional healthcare framework, including personal examinations and the purchase of drugs through traditional pharmacy chains.

Pharmaceutical companies have developed their own DTC programs to simplify access to therapy and directly reduce the patient’s financial burden. Platforms such as NovoCare Pharmacy and LillyDirect allow users who meet specific criteria to receive therapy via direct home delivery.

These programs also operate through a model of manufacturer rebates and pre-defined cash prices, thereby bypassing the administrative and insurance barriers that previously slowed the initiation of therapy.

The development of telemedicine services has further transformed the way healthcare is provided in this area. Platforms such as GoodRx for Weight Loss offer virtual health assessments, electronic prescriptions, and continuous therapy monitoring, thereby increasing accessibility and speeding up initiation.

Such models may also include advanced payment options (pre-defined prices) similar to manufacturer programs, giving patients greater choice when deciding on therapy and its long-term maintenance. 

5.  Insurance Coverage Changes 

During 2026, insurance policies for GLP-1 therapies show a clear divide in approach. While coverage for indications such as Type 2 Diabetes and some cardiovascular conditions is possible, therapies used solely for weight loss face restrictions on reimbursement terms.

• Commercial and employer plans: Individual and employer–sponsored plans continue to cover GLP-1 drugs when indicated for blood sugar control and cardiovascular risk reduction. However, when the primary indication is obesity without comorbidities, coverage is often considered as optional or monitored under rigorous criteria (e.g., BMI thresholds, prior therapy attempts). Some insurers, including some Blue Cross plans, are gradually reducing or completely stopping coverage for drugs like Wegovy, Saxenda, and Zepbound when they are used only for weight loss.
• Medicare and Medicaid: Within public programs, an evaluation of the voluntary model was initiated to balance availability and budget sustainability. Implementation is planned in phases – first through Medicaid plans and then through Medicare plans that cover prescription drugs. In parallel, the introduction of a transition mechanism within the Medicare system is being considered to enable specific access to therapy.
• Cos, Availability, and DTC Alternatives: Given the limited and heterogeneous insurance coverage for weight-loss indications, an increasing number of patients are turning to direct payment and direct-to-consumer (DTC) models. These models can offer more transparent and lower prices through producer programs or fixed cash tariffs. However, since they are not part of the standard insurance system, the question of long-term financial sustainability remains open.

The Bottom Line

In 2026, glucagon-like peptide-1 (GLP-1) receptor agonists continue to shape the treatment paradigm for Type 2 Diabetes, obesity, and metabolic disorders. Key trends include expanding indications, developing new injectable and oral formulations, and increasing therapy availability through direct-to-consumer distribution models.

The insurance situation for GLP-1 therapies remains complex and multi-layered. While some insurers are tightening criteria or eliminating coverage for drugs used solely for weight loss, programs are developing in parallel within the Medicare and Medicaid systems that offer improved access to therapy.

Additionally, expanding the number of medically approved indications may contribute to broader coverage and facilitate patient access to these therapies.